Cipla Ltd Q2 FY2023 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/ms8dmts874idw9hbgf0wdnds.pdf

Key Takeaways


US Generics: The Base Reset and Pipeline

Umang Vohra: “I think this current level of our business at 175 to 180, unless there is something that goes dramatically wrong. I think you could translate this to seeing this as a new base for the business.”

One India: Broad-Based Volume and Reach


Margin Walk and Cost Discipline


Regulatory and Manufacturing Milestones

Umang Vohra: “If the Goa site approval comes, then obviously this will be in track with first quarter of the next financial year, which is the first half of the next calendar year, and if it is delayed, then it could be pushed out by six months.”

Pipeline Beyond the Near-Term Catalysts

Umang Vohra: “Our strategy at least for the US is about being very selective with products, maybe the average R&D spending per asset is higher. But we don't subscribe to the breadth model of assets, where we do more projects necessarily.”

International Markets and Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
Full-year EBITDA margin21% to 22%FY23
Lanreotide market shareReach roughly 15% shareBy end of this year
Generic Advair launchLaunch in H2 FY23, subject to FDA review of responsesH2 FY23
Abraxane launchQ1 FY24 if Goa approved; delayed by six months if notQ1 FY24 or H1 CY24
Lenalidomide repeatabilityRepeatability expected at least for this yearFY23
US business base$175–180 mn as a new baseOngoing, barring dramatic reversal
Leuprolide Depo launchLaunching imminently; slow ramp like LanreotideAnytime now
R&D run rate5.8% of revenueRest of FY23
Long-term R&D ceilingCannot exceed 7% of revenueLong-term
Peptide launchesFirst set of launchesLatter half of H1 FY24
Next inhaler asset filingFiling targetedH2 next calendar year
Biosimilar launchesLaunch expected2028–2030 timeframe
ROCEAccelerating from current 20%Ongoing

Key Metrics

MetricQ2 FY23
Revenue₹5,829 cr, multi-quarter high; 6% reported growth, 12% YoY ex-COVID
EBITDA margin (reported)22.3%, 6% growth over last year; adjusted ~24% ex-COVID inventory charge
EBITDA (reported)₹1,302 cr; adjusted core operating profitability ~₹1,389 cr
Profit after tax₹789 cr, 13.5% of sales
Gross margin63%, 165 bps above last year
R&D spend₹335 cr, 5.8% of revenue; up ₹61 cr YoY
Employee cost₹951 cr, flat sequentially
Other expenses₹1,405 cr, up 12.3% sequentially, driven by higher R&D
Total expenses₹2,366 cr, up 7.2% sequentially
One India revenue growth (ex-COVID)15% YoY; reported growth 6%
Branded prescription growth (ex-COVID)15%, sixth consecutive quarter of market-beating growth
Consumer health annualized revenue₹600 cr+; overall business >20% growth YoY; transferred brands 14% growth
US core formulations sales$179 million, 25% growth YoY
Lanreotide market share9.6%, up from 4.6% in Q1; tracking to ~15% by year-end
Albuterol market share16% as per IQVIA MAT Sep 2022
Arformoterol market share38% as per IQVIA MAT Sep 2022
South Africa private market share7.5%, third position; 7.2% growth vs market 2.8%
Return on capital employed20% for the 12-month period
Full year EBITDA guidance21% to 22%
US business new base guidance$175 mn to $180 mn quarterly